Biclonal gammopathy in a patient taking efalizumab for the treatment of psoriasis

We report a patient who developed biclonal gammopathy of undetermined significance during treatment with efalizumab for psoriasis. This plasma cell disorder was found during the evaluation of the patient’s complaint of mild lower extremity paresthesia. The gammopathy spontaneously remitted following cessation of therapy and has not recurred to date. Given the increasing use and development of biological agents for the treatment of psoriasis and other disorders, this finding and the mechanisms by which it may have occurred is of clinical significance. *Corresponding author: Jeanny B Aragon-Ching, Assistant Professor of Medicine, George Washington University, Medical Faculty Associates, 2150 Pennsylvania Ave., NW, Suite 3-428, Washington DC 20037, USA, Tel: (202) 741-2478; Fax: (202) 741-2487; E-mail: [email protected] Received January 03, 2013; Accepted March 14, 2013; Published March 18, 2013 Citation: Fthenakis A, Wenk KS, Ehrlich A, Aragon-Ching JB (2013) Biclonal Gammopathy in a Patient taking Efalizumab for the Treatment of Psoriasis. J Hematol Thromb Dis 1: 106. doi:10.4172/jhtd.1000106 Copyright: © 2013 Fthenakis A, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.